---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-26-005466"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T15:49:22.799589+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tonix unveils post hoc data: TONMYA pain relief from Day 2; NNT=7, NNH=26

## Summary
- Post hoc analysis of Phase 3 RESILIENT trial (n=457) shows TONMYA pain improvement vs placebo from Day 2, significant through Week 14 (p<0.001).
- Primary endpoint met with LS mean treatment difference of -0.65 in weekly pain score; all key secondary endpoints significant.
- Pooled analysis (n=959) reports NNT for ≥30% pain reduction at Week 14 = 7 (95% CI 5-12); NNH for discontinuation = 26 (95% CI 14-110).
- LHH = 3.7, indicating nearly 4-fold greater likelihood of clinical benefit vs adverse event-related discontinuation.
- TONMYA launched in November 2025 as first fibromyalgia approval in 15 years; mild transient oral hypoesthesia and dysgeusia most common adverse events.

## SEC filing metadata
- accession: 0001999371-26-005466
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937126005466/0001999371-26-005466-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937126005466/tnxp-8k_031026.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-26-005466
- JSON: https://secwatch.observer/filing/0001999371-26-005466.json
- Plain text: https://secwatch.observer/filing/0001999371-26-005466.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.